Strathclyde-founded dermatological device manufacturer Cutitronics has collected further investment from specialty chemicals supplier Croda as the pair aim to win business with personal care brands.
Cutitronics, a UK-based skincare evaluation device manufacturer spun out of University of Strathclyde, has attracted an undisclosed follow-on sum from specialty chemicals supplier Croda International, Insider reported on Thursday.
Founded in 2014, Cutitronics develops handheld devices branded Cutitron that conduct a detailed analysis of skin health to facilitate the prescription of personalised dermatological regimens consisting of products tailored to the user’s specific needs.
The devices connect to a mobile app that tracks the user’s overall skin condition and offer features including a daily skin diary and dosing schedule. Cutitronics will initially market its platform to premium personal care brands, customising the software to reflect each client’s product range.
David Heath, a former research associate and fellow in the Department of Biomedical Engineering co-founded Cutitronics and now acts as CEO.
Croda’s investment is intended to drive compliance testing and updates of Cutitronics‘ technology as the latter aims to complete pilot manufacturing ahead of the release of its first customisable commercial device.
The corporate previously supplied Cutitronics with an undisclosed sum in July 2017, and the pair have teamed up under a strategic partnership to exploit Croda’s experience in the global personal care market.
